Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
NCT ID: NCT00795639
Last Updated: 2015-03-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
183 participants
INTERVENTIONAL
2008-12-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
NCT00796510
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
NCT00811018
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
NCT00034307
A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
NCT01204853
Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
NCT01210443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sitaxsentan
Monotherapy
Sitaxsentan
Sitaxsentan = 100 mg tablet administered orally, once daily
Sitaxsentan Placebo
Monotherapy
Placebo
Sitaxsentan Placebo = 1 tablet administered orally, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sitaxsentan
Sitaxsentan = 100 mg tablet administered orally, once daily
Placebo
Sitaxsentan Placebo = 1 tablet administered orally, once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Fountain Valley, California, United States
Pfizer Investigational Site
Mather, California, United States
Pfizer Investigational Site
Sacramento, California, United States
Pfizer Investigational Site
Englewood, Colorado, United States
Pfizer Investigational Site
Littleton, Colorado, United States
Pfizer Investigational Site
Gainesville, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
Weston, Florida, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Olathe, Kansas, United States
Pfizer Investigational Site
Towson, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Islandia, New York, United States
Pfizer Investigational Site
Stony Brook, New York, United States
Pfizer Investigational Site
Chapel Hill, North Carolina, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Lancaster, Pennsylvania, United States
Pfizer Investigational Site
Lancaster, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
Providence, Rhode Island, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Temple, Texas, United States
Pfizer Investigational Site
Lynchburg, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Veliko Tarnovo, , Bulgaria
Pfizer Investigational Site
Temuco, , Chile
Pfizer Investigational Site
Changsha, Hunan, China
Pfizer Investigational Site
Xi’an, Shanxi, China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Bogotá, Cundinamarca, Colombia
Pfizer Investigational Site
Escazú, Provincia de San José, Costa Rica
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Santo Domingo, República Dominicana, Dominican Republic
Pfizer Investigational Site
Santo Domingo, Santo Domingo Province, Dominican Republic
Pfizer Investigational Site
Guatemala City, Departamento de Guatemala, Guatemala
Pfizer Investigational Site
Hyderabad, Andhera Pradesh, India
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India
Pfizer Investigational Site
Ahmedabad, Gujarat, India
Pfizer Investigational Site
Surat, Gujarat, India
Pfizer Investigational Site
Vadodara, Gujarat, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Coimbatore, Tamil Nadu, India
Pfizer Investigational Site
Madurai, Tamil Nadu, India
Pfizer Investigational Site
George Town, Pulau Pinang, Malaysia
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Lima, , Peru
Pfizer Investigational Site
Lima, , Peru
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Cluj-Napoca, Romania, Romania
Pfizer Investigational Site
Iași, , Romania
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Riyadh, , Saudi Arabia
Pfizer Investigational Site
Belgrade, , Serbia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Cape Town, Western Cape, South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Johannesburg, , South Africa
Pfizer Investigational Site
Stellenbosch, , South Africa
Pfizer Investigational Site
Bangkoknoi, Bangkok, Thailand
Pfizer Investigational Site
Bangkok, , Thailand
Pfizer Investigational Site
Istanbul, Fatih, , Turkey (Türkiye)
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1321001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.